Regulatory Library
Plain English first. The primary source next to it.
This library supports all three certifications. Each entry states the general rule, why it matters, where the answer becomes fact-specific, and links the official source so you can read it yourself. This is education, not legal advice.
RUO labeling
- Does a 'Research Use Only' label decide whether a product is legal?
In short: the label describes an intended use, it does not create one. Conduct decides the legal question.
2 primary sources
- How does FDA decide what a product is 'intended' for if the label says something else?
In short: regulators read the whole picture, including marketing, customer communications, and what a seller knows about actual use.
1 primary source
FDA jurisdiction
- What makes a chemical or compound a 'drug' in the eyes of the law?
In short: intended use turns a substance into a drug. Chemistry alone does not settle the category.
1 primary source
- What is misbranding, and is it different from selling something dangerous?
In short: misbranding is a labeling and communication problem, and it can exist even when a product is exactly what it claims to be chemically.
1 primary source
- Is an 'adulterated' drug the same thing as a contaminated one?
In short: adulteration is a quality and manufacturing problem. Correct paperwork does not cure it.
1 primary source
- Does drug supply chain tracing law have anything to do with selling research chemicals?
In short: prescription drug supply-chain rules govern traceability. RUO material sits outside that system, which is itself a documentation problem.
1 primary source
- Is it legal to personally import a research chemical or unapproved drug from another country?
In short: the personal importation policy is discretion, not a right, and it does not legalize the underlying product.
1 primary source
Human-subject research
- If I test something on myself or a friend, is that 'human subjects research'?
In short: whether the Common Rule applies depends on the activity, the funding, and the institution, not on how a researcher describes themselves.
1 primary source
- Do I need IRB approval before running a study involving people?
In short: independent review exists to protect participants. Whether it is required is a fact-specific determination worth getting in writing.
2 primary sources
- Is a signed waiver or liability release the same thing as informed consent?
In short: consent is a documented process with defined elements, not a signature on a waiver.
1 primary source
- Does self-experimentation get a free pass from research regulations?
In short: experimenting on yourself does not create an exemption from otherwise applicable law.
2 primary sources
- What happens if a researcher has no institutional IRB available at all?
In short: an institution's internal policy and federal requirements are separate layers, and satisfying one does not satisfy the other.
1 primary source
Investigational drugs
- Why can't a compound with promising research data just be sold once someone believes it works?
In short: approval is product-specific and evidence-driven. No education, credential, or label substitutes for it.
2 primary sources
- What is an Investigational New Drug application and who has to file one?
In short: studying an unapproved drug in people generally requires an authorized pathway before the first subject, not after.
2 primary sources
- Can a patient just ask for 'compassionate use' access to an investigational compound?
In short: expanded access is a narrow, supervised route through a physician and FDA. It is not a self-service option.
2 primary sources
- If a researcher both designs a study and administers the substance, do they have extra legal responsibilities?
In short: taking on both roles means taking on both sets of duties, including reporting, recordkeeping, and oversight.
2 primary sources
Marketing and claims
- Can a company just say a product 'supports' or 'boosts' something without proof?
In short: advertising claims need competent and reliable evidence before they are made, and testimonials do not supply it.
2 primary sources
- If a supplier says its lab is 'ISO 17025 accredited' or 'CLIA certified', what does that actually guarantee?
In short: laboratory accreditation describes how a test was run, not whether a product is safe or suitable for any use.
2 primary sources
Compounding and pharmacy
- Is a compounding pharmacy allowed to make a custom version of a drug from research-grade material?
In short: compounding is a regulated activity with defined limits. It is not a general license to prepare unapproved substances.
3 primary sources
Controlled and state law
- If a compound is not on the controlled substances list but is chemically similar to one, is it automatically legal?
In short: controlled-substance analysis is chemical and fact-specific, and most peptides sit outside it. Assume nothing without checking.
2 primary sources
- If something is fine under federal FDA rules, is it automatically fine everywhere in the country?
In short: federal law is the floor, not the ceiling. State rules often decide the practical answer.
1 primary source
Enforcement and litigation
- If a company hasn't received an FDA warning letter, does that mean its products are compliant?
In short: enforcement discretion is not permission, and it can change without notice.
1 primary source
- Does being terminally ill create an automatic legal right to unapproved treatments?
In short: courts have declined to create a general right of access to unapproved treatments. Access questions run through regulatory pathways.
1 primary source